Outcome of partial cystectomy for non-urothelial urinary bladder malignancies in a tertiary care urology unit in Sri Lanka

Umesh Jayarajah, Kasun Herath, Manoj Hilary Fernando, Serozsha Goonewardena
Department of Urology, National Hospital of Sri Lanka, Colombo, Sri Lanka

Keywords: Partial cystectomy; non-urothelial urinary bladder malignancies; outcomes

Abstract

Introduction
Non-urothelial bladder cancers (NUBC) are very aggressive form of tumors and the standard treatment is radical cystectomy which is associated with high morbidity. This study was aimed to describe the outcome of partial cystectomy for selected patients with NUBC in a tertiary care urology unit in Sri Lanka.

Methods
A retrospective analysis of all patients (n=7, males=4) who underwent partial cystectomy for NUBC in a tertiary care urology unit in National Hospital of Sri Lanka over a period of 16 years was done (From 2001 to 2016). All underwent preliminary transurethral resection of bladder tumour (TURBT), histological confirmation and imaging before partial cystectomy. Lymphadenectomy was performed in patients with macroscopic involvement.

Results
The median age was 59 years (range: 34-71). Six patients had haematuria at presentation. The majority of tumours were seen in the anterior wall and dome of the bladder. Four patients had primary adenocarcinoma of the bladder. Others were leiomyosarcoma, small cell cancer and goblet cell carcinoid tumour. The majority had muscle invasive disease as confirmed by histopathology. The patients with signet ring cell carcinoma, leiomyosarcoma and well differentiated adenocarcinoma had favorable outcomes, while patients with papillary carcinoma, small cell carcinoma and goblet cell carcinoid tumour showed poor outcomes.

Conclusion
Partial cystectomy was associated with variable outcomes. Further analyses are necessary to understand the factors associated with favorable outcomes which would be helpful in patient selection.

Introduction
Non-urothelial bladder cancers [NUBC] are a rare and generally aggressive form of tumours accounting for less than 5% of all bladder tumours [1, 2]. Due to the rarity, the understanding of tumour behaviour and effective management strategies are poor. At present, the accepted surgical treatment is radical cystectomy which is associated with high morbidity and poor quality of life [1, 2]. Furthermore, this may be unsuitable for elderly patients with significant comorbidities. Some patients refuse to undergo the surgery in our setting due to the associated functional morbidity. Therefore, such patients with NUBC with potentially resectable tumours were offered partial cystectomy. We report the outcome of partial cystectomy for selected patients with NUBC in a tertiary care urology unit in Sri Lanka.

Methods
Seven patients including 4 males and 3 females, who underwent partial cystectomy for non-urothelial bladder cancers in a tertiary care urology unit in National Hospital of Sri Lanka over a period of 16 years (From 2001 to 2016) were described. All patients underwent transurethral resection of the bladder tumour (TURBT) which was the standard procedure in the initial diagnosis and treatment of bladder cancer. Furthermore, histological confirmation and ultrasonography/ contrast enhanced computed tomography (CT) imaging was performed before partial cystectomy. Lymphadenectomy was performed in patients with macroscopic involvement. Details of patients were collected from hospital and clinic records. Ethical approval was obtained from the Ethics Review Committee of the National Hospital of Sri Lanka.

Results
Table 1 gives the summary of the 7 cases. The median age was 59 years [range: 34-71]. Six patients had haematuria at presentation. The majority of tumours were seen in the anterior wall and dome of the bladder. Four patients had primary adenocarcinoma of the bladder, of which one patient...
Table 1. Clinicopathological characteristics and outcome of patients who underwent partial cystectomy for non-urothelial bladder cancer

| Age | Sex | Presentation | Imaging | Procedure | Lymphadenectomy | Histology | Immunohistochemistry | Outcome | Period without recurrence | Period without progression | Overall survival |
|-----|-----|--------------|---------|-----------|----------------|-----------|----------------------|---------|--------------------------|-----------------------------|-------------------|
| 71  | F   | Haematuria for 2 months | LUS: 2.1 x 1.5 cm Anterior bladder wall growth | Partial cystectomy | Not done | pT2 Signet ring type primary adenocarcinoma of the bladder, no lymphovascular or perineural invasion. | Gastroplasm positive for CK20 and CK7 Nuclear positivity for CK20 Membrane positivity for beta-catenin | Alive at 10 months with no recurrence | >18 months | >18 months | >24 months |
| 64  | F   | Lower abdominal pain for 3 months | CECT: 7.9 x 5.6 x 5 cm mass anterior bladder wall | Partial cystectomy | Not done | pT3b Moderately differentiated adenocarcinoma no lymphovascular invasion. Tumour necrosis present. | Not done | No CT evidence of recurrence at 4 months and asymptomatic at 9 months | 4 months | 4 months | 9 months and thereafter lost to follow up |
| 40  | M   | Haematuria for 1 month | LUS: 3.7 x 2.9 x 3.0 cm dome and anterior wall mass | Partial cystectomy followed by chemotherapy | Not done | pT3 Primary papillary adenocarcinoma no lymphovascular and perineural invasion. | Gastroplasm positive for CK20, CK7, CD10 and PSA: negative | Died after 6 months following surgery | Not known | Not known | 6 months |
| 59  | M   | Haematuria for more than 1 year | CECT: 2.3 x 2.1 cm nodule in anterior bladder wall | Partial cystectomy | Not done | pT2b Well differentiated adenocarcinoma. No lymphovascular and perineural invasion | Not done | Alive at 18 months follow up without recurrence | >23 months | >18 months | >28 months |
| 51  | F   | Haematuria for 2 months | LUS: 2.1 x 2.5 x 2.3 cm Anterior bladder wall growth | Partial cystectomy | Not done | pT4 Moderately differentiated leiomyosarcoma invading the rectovesical muscle | Positive for smooth muscle actin and desmin. Negative for CD117. The Ki67: 70–80% | Alive with no evidence of recurrence at 3.5 years | >13 months | >42 months | >42 months |
| 60  | M   | Haematuria with clots for 3 months | LUS: 3.8 x 3.1 x 1.5 cm Dome and anterior wall mass lesion | Partial cystectomy | Not done | pT2 small cell carcinoma with squamous differentiation | Not done | Died at 6 months | 3 months | 3 months | 6 months |
| 31  | M   | Haematuria with clots for 5 months | LUS: 6 x 5 x 3 cm right posterior wall mass | Partial cystectomy - limited pelvic lymphadenectomy sigmoid colectomy followed by chemotherapy | Macroscopically enlarged nodes were removed | pT4 Goblet cell carcinoid tumour of the bladder. Pelvic lymph nodes positive for tumour Chromogranin A. Occasional positive cells. PDP 0.5 Several positive cells. NSE negative | Died at 9 months | 3 months | - | 9 months |
had signet ring cell adenocarcinoma. Others had leiomyosarcoma, small cell cancer with squamous differentiation and goblet cell carcinoid tumour of the bladder. The majority [n=6] had muscle-invasive disease at surgery as confirmed by histopathology. The patients with signet ring cell carcinoma, leiomyosarcoma and well-differentiated adenocarcinoma had favourable outcomes [Table: 1], while patients with papillary carcinoma, small cell carcinoma and goblet cell carcinoid tumour showed poor outcomes. One patient with pT3b moderately differentiated adenocarcinoma had no CT evidence of recurrence at 4 months and was asymptomatic at nine months but thereafter, she was lost to follow up.

Discussion

Partial cystectomy is considered for selected urothelial carcinoma due to its function preservation and lesser surgical morbidity [3]. Recently, more cases of young patients with NUBC have been treated with partial cystectomy. However, they are restricted to a few case reports and series [4]. We reported our experience on partial cystectomy for NUBC which showed variable outcomes.

In our series, 4 patients had adenocarcinoma of the bladder. The adenocarcinoma of the bladder accounts for 0.5-2% of bladder cancers with the majority having a muscle-invasive disease. These are generally treated with radical cystectomy and pelvic lymph node dissection [5]. The 5-year overall survival rates are 10% to 60% for bladder adenocarcinomas. Of the different histological variants of adenocarcinoma, signet ring cell carcinoma is considered to have the worst outcomes [5]. In our series, 2 patients had a good outcome with no recurrence and of which, one patient had signet-ring cell carcinoma which is known to be associated with the worst prognosis. One patient was lost to follow up but the computed tomography [CT] at 4 months post-op did not show any recurrences. Papillary adenocarcinoma had the worst prognosis with overall survival of only 6 months.

Sarcomas are the commonest mesenchymal cancers of the bladder and leiomyosarcoma is the commonest histology variant. Although initial evidence suggested aggressive tumour biology, a recent larger case series of 35 patients, showed relatively favourable outcomes [recurrence-rate:34%, 5-year disease-specific survival:62%] [6]. In our series, one patient had leiomyosarcoma of the bladder and had an excellent outcome with no detectable recurrence at 5 years.

Neuroendocrine carcinoma of the urinary bladder is very rare, accounting for only 0.35-0.70% of all bladder cancers and is further subdivided into small cell and large cell carcinoma [7]. To date, there is no standard treatment for the disease because of a lack of data due to the rarity of the disease. In a multi-institutional review of 64 patients in the United States 5-year disease-specific survival rates among patients who underwent radical cystectomy was only 16%. Furthermore, the place for cystectomy is doubtful as there is no difference in survival between patients who underwent cystectomy and patients without surgery [7]. Our patient with muscle-invasive small cell carcinoma had a poor outcome with overall survival of only 6 months. Another patient with a goblet cell carcinoid tumour of the bladder also had a poor outcome.

There are no large scale prospective studies analyzing the effectiveness of partial cystectomy for NUBC and current evidence is only restricted to few case reports and case series. We reported our experience which showed variable outcomes following partial cystectomy for NUBC. In our series, some tumours which are believed to have a worse prognosis such as signet ring cell carcinoma and leiomyosarcoma had good outcomes following partial cystectomy. Radical cystectomy is associated with high morbidity due to surgery and poor quality of life and may not be suitable for patients with significant comorbidities. In future, with advances in early detection and accurate staging, partial cystectomy may be offered for selected patients with early NUBC. However, further studies will be required to study the role of partial cystectomy for NUBC in terms of factors associated with outcome and patient selection.

Conclusion

In this series of NUBC, partial cystectomy was associated with variable outcomes. Careful patient selection with specific emphasis on the tumour type, location and staging with prior patient counselling is mandatory. Further analyses are necessary to understand the factors associated with good outcomes following partial cystectomy which would be helpful in patient selection.

All authors disclose no conflict of interest. The study was conducted in accordance with the ethical standards of the relevant institutional or national ethics committee and the Helsinki Declaration of 1975, as revised in 2000.

References

1. Jayarajah U, Herath K, Fernando M, Kuruppu S, Wickramanayaka U, Fernando I, et al. A clinico-pathological study of non-urothelial bladder cancers in a cohort of patients from a tertiary care urology unit in Sri Lanka. Ceylon Medical Journal. 2018;63[2]:92-4. https://doi.org/10.4038/cmj.v63i2.8680
2. Fernando MH, Jayarajah U, Herath KB, de Silva MVC, Goonewardena SAS. Aggressive squamous cell carcinoma of the bladder associated with a history of large bladder stone–a case report. Clinical case reports. 2017;5[10]:1616.

The Sri Lanka Journal of Surgery 2021; 39(1): 22-25
3. Bazzi WM, Kopp RP, Donahue TF, Bernstein M, Russo P, Bochner BH, et al. Partial cystectomy after neoadjuvant chemotherapy: Memorial Sloan Kettering Cancer Center contemporary experience. International scholarly research notices. 2014;2014. https://doi.org/10.1155/2014/702653

4. Jayarajah U, Fernando MH, Herath KB, de Silva VC, Goonewardena SAS. Partial cystectomy for a primary locally advanced leiomyosarcoma of the bladder: a case report and review of the literature. Clinical Case Reports. 2018;6[5]:883. https://doi.org/10.1002/ccr3.1476

5. Dadhania V, Czerniak B, Guo CC. Adenocarcinoma of the urinary bladder. American Journal of Clinical and Experimental Urology. 2015;3[2]:51-63. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539107/

6. Rosser CJ, Slaton JW, Izawa JJ, Levy LB, Dinney CP. Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology. 2003;61[6]:1151-5. https://doi.org/10.1016/s0090-4295[03]00021-9

7. Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, et al. Small cell carcinoma of the urinary bladder. Cancer. 2004;101[5]:957-62. https://doi.org/10.1002/cncr.20456